Gaetano M. De Ferrari - Publications

Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial.

Journal: Circulation

Published: August 31, 2026

Percutaneous Left Stellate Ganglion Block for Drug-Refractory Supraventricular Arrhythmias in Patients with Advanced Heart Failure and Cardiogenic Shock: A Pilot Study.

Journal: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

Published: August 08, 2026

A structured approach to cardiogenic shock: integrating phenotyping, timely circulatory support, and regional care networks.

Journal: Expert review of cardiovascular therapy

Published: July 31, 2026

Incretin-based therapies, alcohol and tobacco use, and acute substance-related events: emerging implications for cardiovascular medicine.

Journal: Journal of cardiovascular pharmacology

Published: July 28, 2026

Preprocedural clinical and angiographic predictors of improved cardiovascular outcomes with final two-stent implantation in coronary bifurcation lesions; the Bifurcation Two-Stent (BTS) score.

Journal: Cardiovascular revascularization medicine : including molecular interventions

Published: July 10, 2026

Gaps in lipid management among high-risk patients without prior MI or stroke: the VESALIUS-REAL global study.

Journal: Clinical research in cardiology : official journal of the German Cardiac Society

Published: July 07, 2026

Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study.

Journal: Journal of the American College of Cardiology

Published: July 07, 2026

Evolocumab and risk of first myocardial infarction: the VESALIUS-CV trial.

Journal: European heart journal

Published: July 07, 2026

Pressure-Volume-Derived Ventricular Energetics Across Mechanical Circulatory Support Strategies in Cardiogenic Shock.

Journal: ASAIO journal (American Society for Artificial Internal Organs : 1992)

Published: June 01, 2026

Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.

Journal: Circulation

Published: May 25, 2026

Physical activity and Brugada ECG pattern during 12-lead Holter monitoring.

Journal: The Journal of sports medicine and physical fitness

Published: May 22, 2026

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial.

Journal: Circulation

Published: May 19, 2026